Tag: AstraZeneca
AstraZeneca India launches Trastuzumab deruxtecan for HER-2 positive metastatic breast cancer...
Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate
AstraZeneca to acquire China’s Gracell Biotechnologies for US $1.2 billion
The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases
AstraZeneca gets CDSCO approval to market its triple drug combination inhalation...
The pressurized metered dose inhaler is recommended for the treatment and maintenance of patients with chronic obstructive pulmonary disease (COPD)
AstraZeneca partners with Roche Diagnostics to improve diagnostic testing for breast...
The collaboration aims to address existing diagnostic challenges, reduce turnaround times, and elevate the overall patient experience
AstraZeneca India gets CDSCO approval for Palivizumab, a preventive therapy for...
In India, Respiratory Syncytial Virus is the most common cause of hospitalization in children <1 years old
Revvity expands access to base editing tech with aim to accelerate...
Reagent launch puts clinically relevant base editing in the hands of preclinical laboratories seeking to accelerate genomic insights and cell therapy research
Inflammatory bowel disease treatments reach inflection point requiring active comparators, says...
The current situation would be best addressed through clinical asset evaluation through trials with active comparators
Boehringer Ingelheim appoints Gagandeep Singh as MD & Head of Human...
Singh joins Boehringer Ingelheim from AstraZeneca, where he was the Managing Director for India and Africa Cluster Head
AstraZeneca India appoints Bhavana Agrawal as Chief Financial Officer
Bhavana succeeds Rajesh Marwaha, who is retiring as CFO and full-time director of the company on September 30, 2023
Revvity signs new license agreement with AstraZeneca for Next-Gen Base Editing...
Non-exclusive agreement provides AstraZeneca access to proprietary gene editing technology to help advance its work in cell therapy